Prasugrel: A Novel P2Y12 Receptor Inhibitor

Itsik Ben-Dor; Mickey Scheinowitz; Ron Waksman

doi:10.1002/9781444306347.ch9

Prasugrel: A Novel P2Y₁₂ Receptor Inhibitor

Itsik Ben-Dor^*, Mickey Scheinowitz, Ron Waksman

^*Corresponding author for this work

Department of Bio-Medical Engineering

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Original language	English
Title of host publication	Pharmacology in the Catheterization Laboratory
Publisher	Wiley-Blackwell
Pages	59-66
Number of pages	8
ISBN (Print)	9781405157049
DOIs	https://doi.org/10.1002/9781444306347.ch9
State	Published - 30 Oct 2009

Keywords

Antiplatelet therapy monitoring
Joint Utilization of Medication to Block Platelets Optimally-Thrombolysis In Myocardial Infarction (JUMBO-TIMI)
OPTIMUS-3 study and prasugrel standard doses with high loading doses
Percutaneous coronary intervention (PCI) following acute coronary syndrome (ACS)
Prasugrel (CS-747, LY640315)-investigational, third-generation thienopyridine
Prasugrel safety and tolerability in healthy volunteers
Prasugrel, novel p2y12 receptor inhibitor
Thienopyridines-class of ADP/P2Y12 receptor inhibitors
Thrombotic thrombocytopenic purpura (TTP)
VerifyNow point of care assay with light transmission aggregometry (LTA)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/9781444306347.ch9

Cite this

@inbook{03c2ec207ef34a6aa18173a7fd3a0483,

title = "Prasugrel: A Novel P2Y12 Receptor Inhibitor",

keywords = "Antiplatelet therapy monitoring, Joint Utilization of Medication to Block Platelets Optimally-Thrombolysis In Myocardial Infarction (JUMBO-TIMI), OPTIMUS-3 study and prasugrel standard doses with high loading doses, Percutaneous coronary intervention (PCI) following acute coronary syndrome (ACS), Prasugrel (CS-747, LY640315)-investigational, third-generation thienopyridine, Prasugrel safety and tolerability in healthy volunteers, Prasugrel, novel p2y12 receptor inhibitor, Thienopyridines-class of ADP/P2Y12 receptor inhibitors, Thrombotic thrombocytopenic purpura (TTP), VerifyNow point of care assay with light transmission aggregometry (LTA)",

author = "Itsik Ben-Dor and Mickey Scheinowitz and Ron Waksman",

year = "2009",

month = oct,

day = "30",

doi = "10.1002/9781444306347.ch9",

language = "אנגלית",

isbn = "9781405157049",

pages = "59--66",

booktitle = "Pharmacology in the Catheterization Laboratory",

publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Prasugrel

T2 - A Novel P2Y12 Receptor Inhibitor

AU - Ben-Dor, Itsik

AU - Scheinowitz, Mickey

AU - Waksman, Ron

PY - 2009/10/30

Y1 - 2009/10/30

KW - Antiplatelet therapy monitoring

KW - Joint Utilization of Medication to Block Platelets Optimally-Thrombolysis In Myocardial Infarction (JUMBO-TIMI)

KW - OPTIMUS-3 study and prasugrel standard doses with high loading doses

KW - Percutaneous coronary intervention (PCI) following acute coronary syndrome (ACS)

KW - Prasugrel (CS-747, LY640315)-investigational, third-generation thienopyridine

KW - Prasugrel safety and tolerability in healthy volunteers

KW - Prasugrel, novel p2y12 receptor inhibitor

KW - Thienopyridines-class of ADP/P2Y12 receptor inhibitors

KW - Thrombotic thrombocytopenic purpura (TTP)

KW - VerifyNow point of care assay with light transmission aggregometry (LTA)

UR - http://www.scopus.com/inward/record.url?scp=84889453692&partnerID=8YFLogxK

U2 - 10.1002/9781444306347.ch9

DO - 10.1002/9781444306347.ch9

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.chapter???

AN - SCOPUS:84889453692

SN - 9781405157049

SP - 59

EP - 66

BT - Pharmacology in the Catheterization Laboratory

PB - Wiley-Blackwell

ER -